Introduction

Acknowledgments

Alberta Health acknowledges the important role Alberta Blue Cross continues to play in the production of the List and in the development of an overall strategy and initiatives to better manage Alberta Health sponsored drug programs.

Eligibility

The Alberta Drug Benefit List (the "List" or "ADBL") defines the Drug Products and Devices that are covered by Alberta government-sponsored drug programs. These programs are for Albertans and their dependents who are covered by:

- 1. the Alberta Blue Cross *Non-Group Coverage (Group 1)* offered by the Alberta Health Care Insurance Plan, or
- 2. the Alberta Blue Cross *Coverage for Seniors (Group 66)* provided to all Alberta senior citizens, or
- 3. the drug coverage provided to individuals approved by Alberta Health for *Palliative Coverage*. (For these individuals the *Palliative Coverage Drug Benefit Supplement* must also be considered), or
- 4. the drug coverage provided to Alberta Human Services clients. (For these clients the *Alberta Human Services Drug Benefit Supplement* must also be considered.)

Additional Notes Regarding Application of the List

- 1. The List is not intended to be used as a scientific reference or prescribing guide.
- 2. Formularies used by hospitals and continuing care facilities are developed independently of the List.
- 3. Drugs are classified according to the Pharmacologic–Therapeutic Classification (PTC) developed by the American Society of Health-System Pharmacists for the purpose of the American Hospital Formulary Service.

Permission to use this system has been granted by the American Society of Health-System Pharmacists. The Society is not responsible for the accuracy of transpositions or excerpts from the original content.

Where necessary, additional PTCs may have been assigned by Alberta Health to facilitate product location in the List.


4. Where appropriate, the *Compendium of Pharmaceuticals and Specialties*, published by the Canadian Pharmacist's Association, was used as a reference source for the trade name, generic name, Manufacturer, strength and dosage form.

The Canadian Pharmacist's Association is not responsible for the accuracy of transpositions or excerpts from the original content.

- 5. Other reference sources used for the trade name, generic name, manufacturer, strength and dosage form are:
 - Completed Drug Notification Form (DNF)
 - Notice of Compliance (NOC)
 - Product Monograph

- 6. Drug Identification Numbers (DINs) and Natural Product Numbers (NPNs) listed reflect current Manufacturer information available as the date this was published.
- 7. Alberta Health reserves the right to make changes, without notice, to the List through the on-line Interactive List, and any such changes to the on-line Interactive List are effective on the date of the change (unless otherwise stated) and regardless of the date of publication of the pdf version or updates.

Legend



The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

Example of Drug Product Listings

08:00	ANTI-INFECTIVE AGENTS 08:12.16.08 ANTIBACTERIALS PENICILLINS (AMINOPENICILLINS)			
	AMOXICILLIN TRIHYDRATE/ CLAVULANATE POTASS 250 MG (BASE) * 125 MG (BASE) ORAL TABLET 00002243350 APO-AMOXI CLAV	и м арх	\$	0.2467 -
28:00	CENTRAL NERVOUS SYSTEM AGENTS 28:08:08 ANALGESICS AND ANTIPYRETICS (OPIATE AGONISTS)			
	OXYCODONE HCL 10 MG ORAL TABLET 00000443948 SUPEUDOL 00002319985 PMS-OXYCODONE 00002240131 OXY-IR	SDZ PMS PUR	\$ \$	0.2397 ← 【4 0.2517 0.4410
• 28:00 2	CENTRAL NERVOUS SYSTEM AGENTS 28:08:04.92 ANALGESICS AND ANTIPYRETICS NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS)			
8	 DICLOFENAC SODIUM 100 MG ORAL SUSTAINED-RELEASE TABLET 00002091194 APO-DICLO SR A 00002261944 SANDOZ DICLOFENAC SR S MAC pricing has been applied based on the LCA 	· · · ·	4 \$	0.4048 0.4048 oated tablets.
08:00	ANTI-INFECTIVE AGENTS 08:12.28.20 ANTIBACTERIALS MISCELLANEOUS ANTIBACTERIALS (LINCOMYCINS)			
	CLINDAMYCIN PHOSPHATE 150 MG / ML (BASE) INJECTION 00002230535 CLINDAMYCIN (60 & 120 ML) 00002230540 CLINDAMYCIN 00000260436 DALACIN C PHOSPHATE	SDZ SDZ PFI	\$ \$ \$	4.1580 4.1580 4.4469
84:00	SKIN AND MUCOUS MEMBRANE AGENTS84:06ANTI-INFLAMMATORY AGENTS			
() () ()	BETAMETHASONE DIPROPIONATE/ SALICYLIC ACID 0.5 MG / G (BASE) * 30 MG / G TOPICAL OINTMENT 00000578436 DIPROSALIC	MFC	\$	0.9084
	EPINEPHRINE 0.15 MG / SYR INJECTION SYRINGE			
6-		VCL MYS	\$ \$	81.0000 85.5588 11
48:00	RESPIRATORY TRACT AGENTS48:10.24ANTI-INFLAMMATORY AGENTS (LEUKOTRIENE MODIFIERS)			
B –	APREPITANT RESTRICTED BENEFIT - This drug product must be prese - Cancer Care "Cancer Centres" (or their designates).	cribed by the Directors of	Alberta H	ealth Services
	80 MG ORAL CAPSULE 00002298791 EMEND 80 MG	MFC	\$	35.6613

The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment.

0

DRUG AND DEVICE REVIEWS

The Minister of Health makes the final decisions on changes to the ADBL (List) after considering the recommendations of the Expert Committee on Drug Evaluation and Therapeutics (Expert Committee), and/or the Canadian Drug Expert Committee (CDEC), and/or Alberta Health.

Manufacturers wishing to have their Drug Product(s) or Device(s) listed on the List are required to make submissions in accordance with the procedures and criteria published in the List.

Common Drug Review

Alberta is a participant in the national Common Drug Review Procedure (CDR Procedure) and considers recommendations from CDEC. Alberta Health and Alberta Blue Cross are not involved in the administration process for CDR submissions and so any questions regarding CDR submissions should be directed to the CDR. Submissions relating to New Drugs, Drugs with a New Indication(s), or New Combination Products that have received a Health Canada Notice of Compliance (NOC) or conditional NOC (NOC/c), or have a pending NOC or NOC/c for the indication(s) to be reviewed should be directed to the CDR for consideration. Submissions to the CDR must comply with the CDR Procedure and Submission Guideline requirements available on the CDR website at <u>https://www.cadth.ca/cadth-proceduresreimbursement-reviews</u>

Expert Committee on Drug Evaluation and Therapeutics Drug Reviews

The Minister of Health has established an Expert Committee on Drug Evaluation and Therapeutics to refine and maintain the List on an ongoing basis. All Drug Products and Devices not eligible for review under the CDR Procedure or the Expedited Review Procedure must be reviewed by the Expert Committee prior to their determination as benefits on the List.

The Expert Committee considers the scientific, therapeutic, clinical and socio-economic merits of Drug Products and Devices. The Committee receives advice and assistance from external consultants and agencies when needed. The Expert Committee makes recommendations on the List to Alberta Health through the Executive Director, Pharmaceuticals & Supplementary Health Benefits.

Interchangeable Reviews

Drug Products may be considered for listing in interchangeable groupings through Expedited Review or Full Review. Expedited Review Drug Products are not required to undergo a Full Review by the Expert Committee. Interchangeable Drug Product submissions will be screened by Alberta Blue Cross to determine eligibility for an Expedited Review and the results provided to Alberta Health. Interchangeable drug submissions requiring a Full Review will be reviewed by the Expert Committee under its usual Drug Product review procedure.

Biosimilar Reviews

Biosimilar Drug Product submissions may be considered through Expedited Review.

Device Reviews

Device submissions may be considered through Expedited Review.

Referrals

Alberta Health at all times and in all circumstances reserves the right to refer any submission to the CDR Procedure and/or the Expert Committee for further advice or for a Full Review.

Deferrals

The Expert Committee and/or Alberta Health reserve the right to defer any submission it deems appropriate in order to ensure that it may complete a review in a manner that protects patient safety and maintains the integrity of the ADBL and the government-sponsored drug programs. Examples of reasons for deferrals include, but are not limited to:

- 1. To request additional information in order to conduct a review and prepare recommendations;
- 2. Where additional time, research and/or consultation is required before a review can be completed or a recommendation can be made;
- 3. Where new or novel issues are raised;
- 4. Where issues, questions or concerns relating to any of the listing criteria or factors arise, including but not limited to:
 - (a) interchangeable safety issues,
 - (b) whether the criteria requires expansion or clarification,
 - (c) the Drug Product or Device,
 - (d) the listing,
 - (e) the price,
 - (f) any other relevant criteria or factor.

Alberta Health Expert Committee on Drug Evaluation and Therapeutics

Committee Members

Margaret GRAY, BSP, FCSHP Chair *Clinical Practice Manager - North* Alberta Health Services Pharmacy Services Edmonton, Alberta

Micheal GUIRGUIS, BScPharm, PhD

Vice-Chair Drug Stewardship Pharmacist Alberta Health Services 1B.140 Kaye Edmonton Clinic 11400 University Ave Edmonton, Alberta T6G 1Z1

Daniel ALTMAN, BSc, MD, FRCPC *Adult Respirologist* 49 Richard Way SW, Suite 103 Calgary, Alberta T3E 7M8

Caitlin CLARKE, BScPharm, PharmD *Clinical Pharmacist* Clarke Pharmacist Services P.O. Box 4537 Barrhead, Alberta T7N 1A4

Naeem LADHANI, BScPharm Manager, Provincial Outpatient Pharmacy Contracts Alberta Health Services 302 South Tower Foothills Medical Centre 1403-29 Street NW Calgary, Alberta T2N 2T9

Nicholas MYERS, BSc, MB, BS, MRCGP (UK) Medical Director, Provincial Primary Care Program Alberta Health Services 10101 Southport Road SW Calgary, Alberta T2W 3N2

Alberta Health Liaison

Andrea NAGLE, BSc Pharm, LLB Executive Director Pharmaceutical & Health Benefits Branch Pharmaceutical & Supplementary Benefits Division Alberta Health 11th Floor, 10025 Jasper Avenue NW Edmonton, Alberta T5J 1S6

Administrative/Scientific Support

Government Scientific and Research Services Alberta Blue Cross 10009-108 Street NW Edmonton, Alberta T5J 3C5

Julia CHAN, BScPharm Team Manager

Amina BABAR, BScPharm *Pharmacist*

Amanda CHUNG, BScPharm *Pharmacist*

Sherry DIELEMAN, BScPharm, MSc Pharmacist